Mark D. Tyson, II, M.D., M.P.H.

Mark D. Tyson II, M.D., is a Professor of Urology, with subspecialty interest in bladder cancer and testis cancer. His clinical focus includes:

• Treatments for muscle invasive and nonmuscle invasive bladder cancer.
• Robotic, open, and single port cystectomy
• Ileal conduits and orthotopic neobladders
• Retroperitoneal lymph node dissection
• Blue light cystoscopy

In addition to his clinical activities, Dr. Tyson is active in research and education, providing mentorship to trainees. He authors expert content and publishes regularly in scientific journals. He is currently recruiting patients for multiple clinical trials for patients with bladder cancer:

• SURF303: A Phase 2A/B Multicenter Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Cancer. 
• MC260501: Phase II Randomized Study of Intravesical Gemcitabine Versus Sequential Gemcitabine and Docetaxel in Patients with BCG-Unresponsive and BCG-Exposed Non-Muscle-Invasive Bladder Cancer.
• BRIGHT: Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer.
• A Phase 2, open-label study to evaluate whether patients with muscle invasive bladder cancer (MIBC) and negative circulating tumor DNA (ctDNA) after neoadjuvant systemic therapy can safely omit cystectomy without compromising clinical outcomes.
• A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects with Low-grade Upper Tract Urothelial Carcinoma
• GAIN - A032303: Gemcitabine Alternating with INtravesical BCG randomized against BCG alone for patients with recurrent high grade Non-Muscle Invasive Bladder Cancer
• ABLE-32 : A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
• QUILT 2.005: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
• ADVANCED-2: A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer
• LEGEND: A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment
• PIVOT-006: A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer Following Transurethral Resection of Bladder Tumor
• PATAPSCO: A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of BCG Administered in Combination with Durvalumab in Adult BCG-naïve, High-risk Non-Muscle-Invasive Bladder Cancer Participants
• CXB-01: A randomized cross-over study to evaluate patient preference and satisfaction with urine-based molecular testing versus cystoscopy for surveillance for nonmuscle invasive bladder cancer.
• Sunrise 3: A phase III open-label, multi-center, randomized study evaluating the efficacy and safety of TAR-200 in combination with cetrelimab versus intravesical BCG in participants with BCG-naïve high-risk nonmuscle invasive bladder cancer
• BOND-003: A phase III study of CG0070 in patients with nonmuscle invasive bladder cancer unresponsive to BCG
• KEYNOTE-676 Cohort A and Cohort B: A phase III, randomized comparator-controlled clinical trial to study the efficacy and safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer that is either persistent or recurrent following BCG induction (Cohort A) or that is naïve to BCG treatment (Cohort B).
• EV-104: A study of intravesical enfortumab vedotin for treatment of patients with nonmuscle invasive bladder cancer.
• SWOG S1602: A phase III randomized trial to evaluate the influence of BCG strain differences and T-cell priming with intradermal BCG before intravesical therapy for BCG-naive high-grade non-muscle invasive bladder cancer.
• TAR-200-103: A multicenter study evaluating safety and efficacy of TAR-200 in subjects with muscle-invasive urothelial carcinoma of the bladder who are ineligible for or refuse cisplatin-based chemotherapy and who are unfit for radical cystectomy.
• UGN-102: A phase IIb, single-arm, multicenter trial to evaluate the efficacy and safety of UGN-102 as a chemoablation agent in patients with low grade non-muscle invasive bladder cancer at intermediate risk of recurrence.

Dr. Tyson also provides second opinions remotely for newly diagnosed bladder and testis cancers.